273 related articles for article (PubMed ID: 16226911)
1. A neural networks-based drug discovery approach and its application for designing aldose reductase inhibitors.
Hu L; Chen G; Chau RM
J Mol Graph Model; 2006 Jan; 24(4):244-53. PubMed ID: 16226911
[TBL] [Abstract][Full Text] [Related]
2. Artificial neural networks-based approach to design ARIs using QSAR for diabetes mellitus.
Patra JC; Singh O
J Comput Chem; 2009 Nov; 30(15):2494-508. PubMed ID: 19373836
[TBL] [Abstract][Full Text] [Related]
3. Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors.
Ferrari AM; Degliesposti G; Sgobba M; Rastelli G
Bioorg Med Chem; 2007 Dec; 15(24):7865-77. PubMed ID: 17870536
[TBL] [Abstract][Full Text] [Related]
4. Pursuing aldose reductase inhibitors through in situ cross-docking and similarity-based virtual screening.
Cosconati S; Marinelli L; La Motta C; Sartini S; Da Settimo F; Olson AJ; Novellino E
J Med Chem; 2009 Sep; 52(18):5578-81. PubMed ID: 19719141
[TBL] [Abstract][Full Text] [Related]
5. How reliable are current docking approaches for structure-based drug design? Lessons from aldose reductase.
Zentgraf M; Steuber H; Koch C; La Motta C; Sartini S; Sotriffer CA; Klebe G
Angew Chem Int Ed Engl; 2007; 46(19):3575-8. PubMed ID: 17394265
[No Abstract] [Full Text] [Related]
6. Exploring structural requirements for aldose-reductase inhibition by 2,4-dioxo-5-(naphth-2-ylmethylene)-3-thiazolidinyl acetic acids and 2-thioxo analogues: Fujita-Ban and Hansch approach.
Soni LK; Kaskhedikar SG
Arch Pharm (Weinheim); 2006 Jun; 339(6):327-31. PubMed ID: 16622827
[TBL] [Abstract][Full Text] [Related]
7. Quantitative structure-activity relationship of spirosuccinimide type aldose reductase inhibitors diminishing sorbitol accumulation in vivo.
Ko K; Won H; Won Y
Bioorg Med Chem; 2006 May; 14(9):3090-7. PubMed ID: 16412651
[TBL] [Abstract][Full Text] [Related]
8. Structure-based optimization of aldose reductase inhibitors originating from virtual screening.
Eisenmann M; Steuber H; Zentgraf M; Altenkämper M; Ortmann R; Perruchon J; Klebe G; Schlitzer M
ChemMedChem; 2009 May; 4(5):809-19. PubMed ID: 19301313
[TBL] [Abstract][Full Text] [Related]
9. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
[TBL] [Abstract][Full Text] [Related]
10. Quantitative structure and aldose reductase inhibitory activity relationship of 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone derivatives.
Ko K; Won Y
Bioorg Med Chem; 2005 Mar; 13(5):1445-52. PubMed ID: 15698760
[TBL] [Abstract][Full Text] [Related]
11. Exploration of QSAR modelling techniques and their combination to rationalize the physicochemical characters of nitrophenyl derivatives towards aldose reductase inhibition.
Soni LK; Gupta AK; Kaskhedikar SG
J Enzyme Inhib Med Chem; 2009 Aug; 24(4):1002-7. PubMed ID: 19514863
[TBL] [Abstract][Full Text] [Related]
12. QSAR prediction of inhibition of aldose reductase for flavonoids.
Mercader AG; Duchowicz PR; Fernández FM; Castro EA; Bennardi DO; Autino JC; Romanelli GP
Bioorg Med Chem; 2008 Aug; 16(15):7470-6. PubMed ID: 18585047
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of potent and selective aldose reductase inhibitors based on pyridylthiadiazine scaffold.
Chen X; Yang Y; Ma B; Zhang S; He M; Gui D; Hussain S; Jing C; Zhu C; Yu Q; Liu Y
Eur J Med Chem; 2011 May; 46(5):1536-44. PubMed ID: 21367494
[TBL] [Abstract][Full Text] [Related]
14. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites.
El-Kabbani O; Wilson DK; Petrash M; Quiocho FA
Mol Vis; 1998 Sep; 4():19. PubMed ID: 9756955
[TBL] [Abstract][Full Text] [Related]
15. Kinetics and molecular docking studies of kaempferol and its prenylated derivatives as aldose reductase inhibitors.
Jung HA; Moon HE; Oh SH; Kim BW; Sohn HS; Choi JS
Chem Biol Interact; 2012 May; 197(2-3):110-8. PubMed ID: 22543015
[TBL] [Abstract][Full Text] [Related]
16. Predictive QSAR modeling of aldose reductase inhibitors using Monte Carlo feature selection.
Nantasenamat C; Monnor T; Worachartcheewan A; Mandi P; Isarankura-Na-Ayudhya C; Prachayasittikul V
Eur J Med Chem; 2014 Apr; 76():352-9. PubMed ID: 24589490
[TBL] [Abstract][Full Text] [Related]
17. Artificial neural network-based drug design for diabetes mellitus using flavonoids.
Patra JC; Chua BH
J Comput Chem; 2011 Mar; 32(4):555-67. PubMed ID: 20806262
[TBL] [Abstract][Full Text] [Related]
18. Structure of human aldose reductase holoenzyme in complex with statil: an approach to structure-based inhibitor design of the enzyme.
El-Kabbani O; Ramsland P; Darmanin C; Chung RP; Podjarny A
Proteins; 2003 Feb; 50(2):230-8. PubMed ID: 12486717
[TBL] [Abstract][Full Text] [Related]
19. High-resolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group.
Steuber H; Zentgraf M; Podjarny A; Heine A; Klebe G
J Mol Biol; 2006 Feb; 356(1):45-56. PubMed ID: 16337231
[TBL] [Abstract][Full Text] [Related]
20. Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations.
Sotriffer CA; Krämer O; Klebe G
Proteins; 2004 Jul; 56(1):52-66. PubMed ID: 15162486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
